health
US centre reports mifamurtide use in 57 osteosarcoma patients
A medRxiv preprint describes retrospective records for 57 osteosarcoma patients given mifamurtide through access programmes at Memorial Sloan Kettering Cancer Center. Outcomes differed by disease setting, and the authors reported no serious adverse events considered possibly or probably related to the drug.